AI assistant
USCOM LIMITED — Regulatory Filings 2014
Feb 26, 2014
65979_rns_2014-02-26_0405cabe-c548-44a0-b9b7-83c4604fd022.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au
==> picture [57 x 49] intentionally omitted <==
M A R K E T A N N O U N C E M E N T
Uscom appoints new European distributor
Thursday 27th of February 2014: Uscom (ASX code: UCM)
Uscom Limited is pleased to announce the appointment of MedCaT as an USCOM 1A distributor for the Netherlands.
MedCaT is a part of the Feles Medici group delivering sophisticated neurologic and cardiovascular devices into the Netherlands and Germany.
Executive Chairman of Uscom, Rob Phillips said, “The appointment of MedCaT is another step in our expanding distributor network. Distribution and sales lead directly to revenue, and are the key to our business. The appointment of MedCaT is further evidence of our growing distribution and sales focus.”
Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure, and for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.
About Uscom
Uscom Limited is an ASX listed cardiovascular medical device company (UCM). Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.
The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.
The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides highly accurate and repeatable measurements of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.
For more information, please visit: http://www.uscom.com.au
Uscom Contacts
Rob Phillips Executive Chairman [email protected]
Catherine Officer Company Secretary [email protected]